Compare · MDLN vs RCEL
MDLN vs RCEL
Side-by-side comparison of Medline Inc. (MDLN) and Avita Medical Inc. (RCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and RCEL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $58.79B, about 430.2x RCEL ($136.6M).
- RCEL has been more active in the news (11 items in the past 4 weeks vs 6 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 6 for RCEL).
- Company
- Medline Inc.
- Avita Medical Inc.
- Price
- -
- -
- Market cap
- $58.79B
- $136.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 6
- 11
- Recent ratings
- 25
- 6
Avita Medical Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.
Latest MDLN
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- SEC Form DEFA14A filed by Medline Inc.
- SEC Form DEF 14A filed by Medline Inc.
- Medline announces first-in-healthcare AI robotics partnership with Symbotic
- Medline to report first quarter 2026 results on May 6, 2026
- Medline launches custom product fulfillment technology called Pick Pack Pro™
- Medline recognizes manufacturing facilities with Golden Cone Safety Award
- Medline receives HIRC Member Choice Awards for supply chain achievement and renews Transparency Badge distinction
- Director Healy Patrick J acquired 577,510 shares, increasing direct ownership by 73% to 1,208,159 units (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,058,524,148 worth of shares (26,131,237 units at $40.51) and disposed of 2,088,086 shares (SEC Form 4)
Latest RCEL
- Avita Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- AVITA Medical Names Cary Vance as Chief Executive Officer
- AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
- AVITA Medical to Announce First Quarter 2026 Financial Results
- SEC Form DEF 14A filed by Avita Medical Inc.
- AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
- AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
- SEC Form EFFECT filed by Avita Medical Inc.
- SEC Form PRE 14A filed by Avita Medical Inc.
- AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness